Mucosolvan (Ambroxol Hydrochloride)

Ambroxol stimulates serous cells in the respiratory lining to increase the secretion of thin, watery fluid. This action lowers mucus viscosity and enhances ciliary movement, which together improve the clearance of mucus and trapped particles from the airways, facilitating easier expectoration.

The appropriate dose of Mucosolvan is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and route of administration. Dosage recommendations are provided in the product labeling and should be followed exactly as instructed by the prescriber.

Safety data for Ambroxol during pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Mucosolvan to pregnant or nursing women. Consultation with a qualified professional is essential for individualized advice.

To request Mucosolvan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Mucosolvan (Ambroxol) differs from agents such as N‑acetylcysteine by primarily stimulating serous secretion rather than directly breaking disulfide bonds in mucus. Both classes reduce mucus thickness, but Ambroxol may have additional anti‑inflammatory properties, while N‑acetylcysteine is often used for its antioxidant effects.

Mucosolvan should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight. Ensure the container is tightly closed when not in use to maintain stability and potency.

Mucosolvan is available for oral administration as a syrup or tablet and for inhalation as a nebulised solution. The route and method of delivery are chosen by the prescriber according to the patient’s condition, age and ability to use the selected device.

The most serious adverse reactions include severe allergic responses such as angioedema, anaphylaxis, and rare skin disorders like Stevens‑Johnson syndrome. Immediate medical attention is required if any signs of a serious hypersensitivity reaction appear.

Mucosolvan is contraindicated in individuals with known hypersensitivity to ambroxol or any excipients in the formulation. Caution is also advised for patients with severe liver disease, uncontrolled asthma, or those taking interacting medications without medical supervision.